EMERGING PUBLIC BIOTECH

SUPERNUS PHARMACEUTICALS INC (SUPN)

Rockville, United States · North America
NEUROLOGY
EMERGING PUBLIC BIOTECH
HEADQUARTERS
Rockville, United States
TICKER
SUPN
SEGMENT
Emerging Public Biotech
THERAPY AREAS
Neurology
KEY PRODUCTS
PRODUCTDETAILS
Qelbree
COMPANY OVERVIEW

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the pr…

SUPERNUS PHARMACEUTICALS INC — FULL INTELLIGENCE

Live regulatory signals, patent cliffs, financials, tariff exposure and pipeline — all free on PharmaSignal.

OPEN PLATFORM →